TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

Advancements in MS include promising therapies like BTK inhibitors and myelin repair, evolving biomarkers, and a focus on cognition, signaling a promising future in precision medicine.

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain and spinal cord ...

Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

People with multiple sclerosis (pwMS) face a lifelong, slowly progressive disease that remains incurable despite new therapies. A key part of helping pwMS and their families or support group to ...

Appealing an insurance claim denial with multiple sclerosis often requires following the rules and being persistent.

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.